Investors

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Documents

Governance

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Contact Us

Management Team

Thomas LaVoy

Thomas LaVoy

Chairman of the Board and Chief Executive Officer

Mr. LaVoy served as a Director of the Company since 2005 until his appointment as Chairman of the Board effective January 7, 2016 and his subsequent appointment as Chairman of the Board and Chief Executive Officer effective February 15, 2016.

Mr. LaVoy brings more than 35 years of experience leading and building successful, publicly traded businesses. With SuperShuttle International, a leader in the transportation industry, Mr. LaVoy serve as Deputy Chief Operating Officer, President of Corporate Services and Chief Financial Officer. Mr. LaVoy was instrumental in developing SuperShuttle’s strategic growth plans which included: revenue growth from $35 million in 1997 to more than $340 million in 2015; acquiring more than 30 businesses; expanding operations to more than 50 locations; and spearheading the acquisition of the business by a large international partner, Veolia Transportation Inc., in 2006.

Prior to his tenure at SuperShuttle, Mr. LaVoy served as CFO of Photocomm, Inc., a leader in solar electric manufacturing, engineering and distribution, from 1987 to 1997. During his term with this small public company, he oversaw the reorganization and access of working capital from shareholders, taking the company public in 1998, and revenue growth from $5 million to over $25 million in fewer than ten years.

William A. Cavanagh, III

William A. Cavanagh, III

Chief Operating Officer

William Cavanagh, III served the Company as Interim Chief Executive Officer from January to February 2016, and Vice-President of Research and Development from January 2010 until January 2016 when he was appointed Chief Operating Officer.

Mr. Cavanagh began his extensive career in cancer treatment technologies in the early 1990s, when he helped head research and development of a therapy involving the insertion of radioactive sources directly into the prostate for the treatment of prostate cancer (prostate brachytherapy). He has designed several cancer treatment-related studies, is listed as an author on 34 peer-reviewed publications, and is the listed inventor on a U.S. patent application detailing a novel treatment for cancer.

Mr. Cavanagh has also served as Director of the Haakon Ragde Foundation for Advanced Cancer Studies in Seattle, Washington, where he lead the research foundation in the selection of viable research projects directed at treating advanced cancers.

Michael L. Krachon

Michael L. Krachon

Vice President of Sales and Marketing

Michael L. Krachon brings more than 20 years’ experience of progressive growth in sales and marketing in the medical industry. Mr. Krachon joined Isoray in March of 2016 as Vice President of Sales & Marketing. Mr. Krachon was previously employed by C.R. Bard Inc., since 2001, and was a key member of the Bard Urological / Bard Medical Divisions which developed brachytherapy devices and delivery systems for the U.S. and international markets. He was the leader of the brachytherapy commercial team, which grew to be the global brachytherapy market leader.

Mr. Krachon assisted in the business unit’s strategic planning, development of the international business segment and creating and delivering the international product launches which resulted in market leadership across Europe, Japan and Africa. Mr. Krachon has been instrumental in successfully supporting the industry through congressional lobbying efforts to re-establish reimbursement codes for brachytherapy. He served as Chairman of the Coalition for Advancement of Brachytherapy from 2009 to 2016 and has been recognized as a national speaker for brachytherapy by the industry. Mr. Krachon received a B.S.E. in biomedical engineering from Duke University and an M.B.A. from the Goizueta Business School at Emory University.

Breakthroughs in brachytherapy by Cesium Pioneers.

Doctors across the US are using Cesium-131 by Isoray in powerful ways with great outcomes. Check out their work.
Learn More
The ability to deliver high concentrated radiation treatment in a tightly controlled area at the time of surgery really allows us to customize and individualize cancer treatment for our patients. Dr. Adam J. Luginbuhl, MD

Otolaryngology/Head & Neck Surgery - Head & Neck Cancers, Thomas Jefferson University Hospital

Prostate Cancer News Today: “Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality”

“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward,...
Read More

IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131”

At Median 5.5 Years Post-Treatment, Return to Baseline is Sustained RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a...
Read More

ABS 2017 Insights and Takeaways

A thorough discussion on value, detailed brachytherapy delivery techniques and ways clinicians can reach new patients: Isoray's ABS 2017 insights and takeaways including Dr. Steven Frank, Dr. Alex Hsi and Harvard Business School Professor Emeritus Dr. Robert Kaplan.
Read More

Isoray Patients Tell Their Stories

Herbert L   During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests...
Read More

IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the...
Read More